{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:58:38Z","timestamp":1780894718169,"version":"3.54.1"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtct.2025.10.023","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:30:59Z","timestamp":1761856259000},"page":"261-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4129-9102","authenticated-orcid":false,"given":"Candelaria","family":"Deimundo Roura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-3911","authenticated-orcid":false,"given":"Persis","family":"Amrolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Buechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5088-7621","authenticated-orcid":false,"given":"Emily M.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayne H.","family":"Rouce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8420","authenticated-orcid":false,"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2025.10.023_bib0001","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/s41375-023-02042-4","article-title":"Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"37","author":"Stackelberg A","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.023_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jtct.2025.10.023_bib0003","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"9967","key":"10.1016\/j.jtct.2025.10.023_bib0004","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"The Lancet"},{"issue":"224","key":"10.1016\/j.jtct.2025.10.023_bib0005","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"25","key":"10.1016\/j.jtct.2025.10.023_bib0006","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2025.10.023_bib0007","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.023_bib0008","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.10.023_bib0009","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric b-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0010","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.023_bib0011","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2025.10.023_bib0012","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.023_bib0013","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.023_bib0015","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0016","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0017","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","article-title":"Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium","volume":"7","author":"Stefanski","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.023_bib0018","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.023_bib0019","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.10.023_bib0020","series-title":"Blood advances","first-page":"1961","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","author":"Fabrizio","year":"2022"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.023_bib0021","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.15973","article-title":"Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"186","author":"Nagler","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.023_bib0022","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.jtct.2025.10.023_bib0023","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.10.023_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01841","article-title":"Joint modeling of immune reconstitution post haploidentical stem cell transplantation in pediatric patients with acute leukemia comparing CD34+-selected to CD3\/CD19-depleted grafts in a retrospective multicenter study","volume":"9","author":"Salzmann-Manrique","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0025","doi-asserted-by":"crossref","first-page":"786017","DOI":"10.3389\/fped.2021.786017","article-title":"Immune reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions","volume":"9","author":"Yanir","year":"2022","journal-title":"Front Pediatr"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.023_bib0026","first-page":"146","article-title":"Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL","volume":"142","author":"Del Bufalo","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.10.023_bib0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood.2023020813","article-title":"Pembrolizumab in PMBCL: can it go the distance?","volume":"142","author":"Giulino-Roth","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0028","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-025-01260-6","article-title":"Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation","volume":"15","author":"Lussana","year":"2025","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.023_bib0029","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.023_bib0030","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.023_bib0031","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy","volume":"6","author":"Holland","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.023_bib0032","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.023_bib0033","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a pediatric real world CAR Consortium Report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.023_bib0034","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.023_bib0035","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1182\/bloodadvances.2020001450","article-title":"Bilateral retinal detachment after chimeric antigen receptor T-cell therapy","volume":"4","author":"Denton","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.023_bib0036","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S1470-2045(19)30861-7","article-title":"Trafficking of CAR T cells to sites of subclinical leukaemia cutis","volume":"21","author":"O\u2019Reilly","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.023_bib0037","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","article-title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Laetsch","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.10.023_bib0038","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153262","article-title":"Tisagenlecleucel therapy is safe and effective for children with down syndrome with ALL in first relapse","volume":"138","author":"Krueger","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-022-03389-7","article-title":"Conditioning regimens for inborn errors of immunity: current perspectives and future strategies","volume":"116","author":"Nishimura","year":"2022","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.023_bib0040","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/bjh.20244","article-title":"Successful combined anti-CD19 immunotherapy of relapsed acute lymphoblastic leukaemia in a child with Nijmegen breakage syndrome","volume":"207","author":"Oszer","year":"2025","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.023_bib0041","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/bloodadvances.2024012638","article-title":"Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL","volume":"9","author":"Annesley","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0042","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.023_bib0043","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.023_bib0044","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","article-title":"Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children","volume":"34","author":"Pan","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.023_bib0045","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.10.023_bib0046","doi-asserted-by":"crossref","unstructured":"Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations Special Report 142, 2023. Available from:http:\/\/ashpublications.org\/blood\/article-pdf\/142\/10\/865\/2076367\/blood_bld-2023-020578-main.pdf. Accessed September 10, 2025.","DOI":"10.1182\/blood.2023020578"},{"key":"10.1016\/j.jtct.2025.10.023_bib0047","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018"},{"key":"10.1016\/j.jtct.2025.10.023_bib0048","series-title":"Pediatr Blood Cancer","article-title":"Hypogammaglobulinemia in children receiving targeted immunotherapies for B lineage malignancies: Practical Guidance for Assessment and Management","author":"Long","year":"2025"},{"key":"10.1016\/j.jtct.2025.10.023_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012436","article-title":"Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL","volume":"13","author":"Culbert","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0050","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.023_bib0051","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-021-00474-4","article-title":"Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer","volume":"18","author":"Ragoonanan","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.jtct.2025.10.023_bib0052","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0053","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"B Leahy","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0055","first-page":"294","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.023_bib0056","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0057","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.10.023_bib0058","doi-asserted-by":"crossref","unstructured":"Epperly R, Shah NN. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. Available from: http:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/77\/2175549\/77epperly.pdf. Accessed September 10, 2025.","DOI":"10.1182\/hematology.2023000422"},{"key":"10.1016\/j.jtct.2025.10.023_bib0059","unstructured":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series."},{"issue":"2","key":"10.1016\/j.jtct.2025.10.023_bib0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ijlh.13375","article-title":"Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients","volume":"43","author":"Wang","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0061","first-page":"1477","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0062","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.10.023_bib0063","doi-asserted-by":"crossref","unstructured":"Nair MS, Silbert SK, Rejeski K, et al. Development of ALL-hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Available from:http:\/\/ashpublications.org\/blood\/article-pdf\/145\/11\/1136\/2359267\/blood_bld-2024-025910-main.pdf. Accessed September 10, 2025.","DOI":"10.1182\/blood.2024025910"},{"key":"10.1016\/j.jtct.2025.10.023_bib0064","unstructured":"Naik S, Selukar S, Talleur AC, et al. Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel. Available from:http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2025016824\/2403862\/bloodadvances.2025016824.pdf Accessed September 10, 2025."},{"issue":"7","key":"10.1016\/j.jtct.2025.10.023_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report","volume":"9","author":"Baur","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2025.10.023_bib0066","doi-asserted-by":"crossref","unstructured":"Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations Special Report. 142. 2023. Available from:http:\/\/ashpublications.org\/blood\/article-pdf\/142\/10\/865\/2076367\/blood_bld-2023-020578-main.pdf. Accessed September 10, 2025.","DOI":"10.1182\/blood.2023020578"},{"key":"10.1016\/j.jtct.2025.10.023_bib0067","series-title":"CD341-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. 6","first-page":"4715","author":"Mullanfiroze","year":"2022"},{"key":"10.1016\/j.jtct.2025.10.023_bib0068","article-title":"Allogeneic CD34+ selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection","volume":"70","author":"Lipsitt","year":"2023"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.023_bib0069","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.023_bib0070","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2025.10.023_bib0071","unstructured":"Braig F, Brandt A, Goebeler M, et al. Brief report lymphoid neoplasia. 2017;"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0072","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI39748","article-title":"CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency","volume":"120","author":"van Zelm","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2025.10.023_bib0073","unstructured":"Silbert S, Bataller A, John Simmons S, et al. Russian Federation) Regina Myers (Children\u2019s Hospital of Philadelphia, United States) Elena Zerkalenkova (Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Russian Federation) Hao-Wei Wang (National Institutes of Health, United States) Alexandra Kovach) Armando Martinez (National Institutes of Health). Available from:http:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024026655\/2367646\/blood.2024026655.pdf. Accessed September 10, 2025."},{"issue":"10","key":"10.1016\/j.jtct.2025.10.023_bib0074","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.023_bib0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/2326-6066.CIR-21-0626","article-title":"Regulatory programs of B-cell activation and germinal center reaction allow B-ALL escape from CD19 CAR T-cell therapy","volume":"10","author":"Im","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"12_Supplement","key":"10.1016\/j.jtct.2025.10.023_bib0076","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-2886","article-title":"Abstract 2886: Antigen internalization and its prevention during treatment with bispecific antibodies","volume":"82","author":"Klimovich","year":"2022","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.023_bib0077","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"issue":"7750","key":"10.1016\/j.jtct.2025.10.023_bib0078","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0079","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2093426","article-title":"Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality","volume":"11","author":"Schoutrop","year":"2022","journal-title":"Oncoimmunology"},{"issue":"18","key":"10.1016\/j.jtct.2025.10.023_bib0080","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.023_bib0081","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41419-023-05829-6","article-title":"Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia","volume":"14","author":"Sugita","year":"2023","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0083","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","article-title":"Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Ceolin","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0084","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.023_bib0085","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.023_bib0086","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: A single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.023_bib0087","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0088","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","article-title":"Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma","volume":"9","author":"de Oliveira Canedo","year":"2025","journal-title":"Blood Adv [Internet]"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.023_bib0089","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.10.023_bib0090","first-page":"2587","article-title":"CAR-T cell persistence in the treatment of leukemia and lymphoma","volume":"62","author":"Gupta","year":"2021"},{"key":"10.1016\/j.jtct.2025.10.023_bib0091","unstructured":"Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. 2011; Available from: www.clinialtrials.gov. Accessed September 10, 2025."},{"key":"10.1016\/j.jtct.2025.10.023_bib0092","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: Building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nature Rev Cancer"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.023_bib0093","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2025.10.023_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","article-title":"Memory T cell, exhaustion, and tumor immunity","volume":"43","author":"Ando","year":"2020","journal-title":"Immunol Med"},{"key":"10.1016\/j.jtct.2025.10.023_bib0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0096","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.ircmb.2018.05.007","article-title":"The single-cell phenotypic identity of human CD8 + and CD4 + T cells","volume":"341","author":"Brummelman","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0097","unstructured":"Hashimoto M, Kamphorst AO, Im J, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. 2025;14:55. https:\/\/doi.org\/10.1146\/annurev-med-012017. Accessed September 10, 2025."},{"issue":"9","key":"10.1016\/j.jtct.2025.10.023_bib0098","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0099","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2025.10.023_bib0100","doi-asserted-by":"crossref","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.023_bib0101","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.10.023_bib0102","unstructured":"Ma L, Dichwalkar T, Chang JYH, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Available from: https:\/\/www.science.org. Accessed September 10, 2025."},{"key":"10.1016\/j.jtct.2025.10.023_bib0103","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0294-6","article-title":"Prospects for combined use of oncolytic viruses and CAR T-cells","volume":"5","author":"Ajina","year":"2017","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.jtct.2025.10.023_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: Joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.jtct.2025.10.023_bib0106","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.jtct.2025.10.023_bib0107","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","article-title":"The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function","volume":"184","author":"Johnson","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0108","doi-asserted-by":"crossref","first-page":"617","DOI":"10.34172\/apb.2020.074","article-title":"Acellular Wharton\u2019s Jelly, potentials in T-cell subtypes differentiation, activation and proliferation","volume":"10","author":"Talebi","year":"2020","journal-title":"Adv Pharm Bull"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.023_bib0109","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jcyt.2014.12.002","article-title":"Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2","volume":"17","author":"Gargett","year":"2015","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.023_bib0110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/cgt.2008.21","article-title":"In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method","volume":"15","author":"Yu","year":"2008","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.023_bib0111","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/hum.2017.237","article-title":"Influence of retronectin-mediated T-cell activation on expansion and phenotype of CD19-specific chimeric antigen receptor T cells","volume":"29","author":"Stock","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtct.2025.10.023_bib0112","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtm.2022.12.002","article-title":"Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors","volume":"28","author":"Braun","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"16","key":"10.1016\/j.jtct.2025.10.023_bib0113","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","article-title":"Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers","volume":"30","author":"Fischer-Riepe","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2025.10.023_bib0114","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1134\/S0006297919070022","article-title":"The role of checkpoint inhibitors and cytokines in adoptive cell-based cancer immunotherapy with genetically modified T cells","volume":"84","author":"Gershovich","year":"2019","journal-title":"Biochemistry (Moscow). Pleiades J"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.023_bib0115","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ajh.26519","article-title":"Results of ARI-0001 CART19 cell therapy in patients with relapsed\/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease","volume":"97","author":"Ortiz-Maldonado","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.023_bib0116","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-024-03035-1","article-title":"Enhancing pediatric access to cell and gene therapies","volume":"30","author":"Mackall","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2025.10.023_bib0117","series-title":"ACT to sustain: adoptive cell therapy to sustain access to non-commercialized genetically modified cell therapies. 30","first-page":"776","author":"Gardner","year":"2024"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0118","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01038-2","article-title":"Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme","volume":"14","author":"Oporto Espuelas","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2025.10.023_bib0119","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-Term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.023_bib0120","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2025.10.023_bib0121","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.10.023_bib0122","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115599","article-title":"Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission","volume":"132","author":"Summers","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.023_bib0123","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"10.1016\/j.jtct.2025.10.023_bib0124","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study","volume":"116","author":"Sun","year":"2010","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.10.023_bib0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2024-201946","article-title":"\"Real World\u201d outcome of hematopoietic stem cell transplantation after CAR19 T cell therapy in children and adults with B-ALL: A gocart coalition study on behalf of the PDWP, ALWP, and Ctiwp of the EBMT","volume":"144","author":"Ottaviano","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.023_bib0126","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/bloodadvances.2024012885","article-title":"Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia","volume":"8","author":"Myers","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.023_bib0127","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","article-title":"Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy","volume":"8","author":"Gabelli","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.023_bib0128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.19551","article-title":"Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"205","author":"Othman","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.023_bib0129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies","volume":"20","author":"Maude","year":"2014","journal-title":"The Cancer Journal"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.023_bib0130","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.10.023_bib0131","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy [Internet]","author":"Hay","year":"2019","journal-title":"Immunobiol Immunother"},{"key":"10.1016\/j.jtct.2025.10.023_bib0132","article-title":"Consolidative hematopoietic stem cell transplantation after CD19 CAR-T cell therapy for acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2025.10.023_bib0133","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/453840a","article-title":"Translational research: crossing the valley of death","volume":"453","author":"Butler","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2025.10.023_bib0134","doi-asserted-by":"crossref","unstructured":"Newman H, Li Y, Liu H, et al. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Immunobiol Immunother. Available from:http:\/\/ashpublications.org\/blood\/article-pdf\/141\/6\/609\/2075090\/blood_bld-2022-017866-main.pdf. Accessed September 10, 2025.","DOI":"10.1182\/blood.2022017866"},{"issue":"23","key":"10.1016\/j.jtct.2025.10.023_bib0135","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.10.023_bib0136","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ccell.2023.10.002","article-title":"Bringing CAR T cell therapy trials to underserved populations","volume":"41","author":"Badr","year":"2023","journal-title":"Cancer Cell. Cell Press"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.023_bib0137","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jtct.2024.09.004","article-title":"Proceedings of the 2024 Third Annual ASTCT-NMDP ACCESS Initiative Workshop","volume":"30","author":"Auletta","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.10.023_bib0138","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.023_bib0139","doi-asserted-by":"crossref","first-page":"73.e1","DOI":"10.1016\/j.jtct.2021.11.019","article-title":"Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:11:35Z","timestamp":1780891895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666636725015271"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}